Treatment-resistant Schizophrenia Clinical Trials

11 recruiting

Frequently Asked Questions

Common questions about Treatment-resistant Schizophrenia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Not Applicable

Deep Brain Stimulation in Treatment Resistant Schizophrenia

Treatment-resistant Schizophrenia
Johns Hopkins University6 enrolled1 locationNCT02361554
Recruiting
Phase 4

Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR.

Treatment-resistant SchizophreniaTreatment- Resistant Bipolar Disorder
Dr. Stavroula Rakitzi40 enrolled1 locationNCT07047651
Recruiting
Not Applicable

Magnetic Seizure Therapy for Schizophrenia - Trial

SchizophreniaTreatment-resistant SchizophreniaSchizoaffective Disorder
Centre for Addiction and Mental Health80 enrolled2 locationsNCT06672588
Recruiting
Not Applicable

Maintenance ElectroConvulsive Therapy in Clozapine RESISTant Schizophrenia - the MECT-RESIST Trial

SchizophreniaTreatment-resistant Schizophrenia
Central Institute of Mental Health, Mannheim140 enrolled14 locationsNCT06456983
Recruiting
Phase 3

Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia

Treatment-resistant Schizophrenia
Newron Pharmaceuticals SPA400 enrolled5 locationsNCT07184619
Recruiting
Not Applicable

Cognitive Behavioral Therapy for Sleep and Circadian Disturbances (CBT-I) in Treatment-Resistant Schizophrenia

Treatment-Refractory SchizophreniaTreatment-resistant Schizophrenia
Jimmi Nielsen60 enrolled1 locationNCT06749444
Recruiting
Not Applicable

Real-time fMRI Neurofeedback in Patients With Schizophrenia and Auditory Hallucinations

SchizophreniaTreatment-resistant SchizophreniaAuditory Hallucination
Boston VA Research Institute, Inc.104 enrolled1 locationNCT05299749
Recruiting
Not Applicable

Reduction of Auditory-Verbal Hallucinations in Schizophrenia Through Cortical Neuromodulation

Treatment-resistant Schizophrenia
Centre Hospitalier St Anne20 enrolled1 locationNCT06361160
Recruiting
Not Applicable

Effect of Atenolol Versus Ivabradine on HRV in TRS Patients on Clozapine With Tachycardia: A Randomised Control Trial.

Treatment-resistant SchizophreniaTachycardiaHeart Rate Variability+1 more
All India Institute of Medical Sciences, Bhubaneswar40 enrolled1 locationNCT06505668
Recruiting
Early Phase 1

The Role of Glutamatergic Function in the Pathophysiology of Treatment-resistant Schizophrenia

Treatment-resistant SchizophreniaHealthy (Controls)Treatment-responsive Schizophrenia
King's College London288 enrolled1 locationNCT06270108
Recruiting

Dundrum Forensic Redevelopment Evaluation Study: D-FOREST Study.

ObesityCardiovascular DiseasesSchizophrenia+9 more
Health Service Executive, Ireland350 enrolled1 locationNCT05074732